|
Delayed
Berne S.E.
|
5-day change | 1st Jan Change | ||
| - CHF | -.--% |
|
-.--% | - |
| Market Cap | 5.93B 5.08B 4.75B 4.35B 8.2B 568B 8.29B 56.26B 21.88B 285B 22.27B 21.79B 943B | P/E 2026 * |
46.5x | P/E 2027 * | 26.3x |
|---|---|---|---|---|---|
| Enterprise Value | 4.06B 3.48B 3.25B 2.98B 5.62B 389B 5.67B 38.51B 14.98B 195B 15.24B 14.91B 646B | EV / Sales 2026 * |
3.23x | EV / Sales 2027 * | 2.76x |
| Free-Float |
92.69% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PTC Therapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Matthew Klein
CEO | Chief Executive Officer | 54 | 21/03/2023 |
Pierre Gravier
DFI | Director of Finance/CFO | 41 | 12/07/2023 |
| Chief Tech/Sci/R&D Officer | - | 30/09/2017 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 31/10/2004 | |
Allan Jacobson
CHM | Chairman | 80 | 30/03/1998 |
David Southwell
BRD | Director/Board Member | 65 | 30/11/2005 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 5.83B | |
| -0.67% | +5.39% | +75.21% | +127.54% | 1,119B | |
| +1.04% | +4.07% | +52.29% | +65.39% | 651B | |
| -0.17% | +5.67% | +25.60% | +80.40% | 468B | |
| -1.38% | +4.02% | +41.64% | +42.38% | 374B | |
| -0.52% | +2.72% | +24.32% | +41.06% | 302B | |
| -1.06% | +4.76% | +1.19% | +12.65% | 259B | |
| +1.03% | +5.83% | +51.11% | +72.96% | 238B | |
| -0.53% | +2.34% | -17.77% | -53.66% | 208B | |
| +0.42% | +5.63% | +27.86% | +92.24% | 181B | |
| Average | -0.18% | +4.81% | +31.27% | +53.44% | 422.21B | |
| Weighted average by Cap. | -0.23% | +4.95% | +43.93% | +72.99% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.26B 1.08B 1.01B 920M 1.74B 120B 1.75B 11.91B 4.63B 60.36B 4.71B 4.61B 200B | 1.37B 1.17B 1.1B 1B 1.89B 131B 1.91B 12.99B 5.05B 65.85B 5.14B 5.03B 218B |
| Net income | 144M 124M 116M 106M 200M 13.81B 202M 1.37B 532M 6.94B 542M 530M 22.95B | 216M 185M 173M 159M 299M 20.72B 303M 2.05B 798M 10.4B 813M 795M 34.43B |
| Net Debt | -1.87B -1.6B -1.5B -1.37B -2.59B -179B -2.62B -17.75B -6.9B -89.97B -7.03B -6.87B -298B | -2.15B -1.84B -1.72B -1.57B -2.97B -205B -3B -20.35B -7.91B -103B -8.06B -7.88B -341B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PTCT Stock
- P91 Stock
Select your edition
All financial news and data tailored to specific country editions
